Masatoshi Nakamura1, Kayoko Ohnishi2, Hitoshi Ishikawa1, Kensuke Nakazawa3, Toshihiro Shiozawa3, Toshiyuki Okumura1, Ikuo Sekine4, Yukio Sato5, Nobuyuki Hizawa3, Hideyuki Sakurai1. 1. Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan. 2. Department of Radiation Oncology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan ohnishi@pmrc.tsukuba.ac.jp. 3. Department of Respiratory Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan. 4. Department of Medical Oncology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan. 5. Department of Thoracic Surgery, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Abstract
BACKGROUND/AIM: To evaluate the outcome of definitive salvage radiotherapy (RT) in non-small cell lung cancer (NSCLC) patients with oligo-recurrence in regional lymph nodes after surgery. PATIENTS AND METHODS: Between January 2003 and December 2016, 33 patients with NSCLC were reviewed from radiotherapy database at our hospital. All patients received photon or proton salvage RT for metastases in the regional lymph nodes. RESULTS: The median follow-up from salvage RT was 35.2 (range=5.9-89.6) months. Recurrences occurred in 18 (55%) patients, and the 3-year overall and progression-free survival rates were 63.8% and 45.1%, respectively. Regional and local control improved patients' survival and these control rates were increased by use of concurrent chemotherapy (p=0.039) and proton RT (p=0.084). No grade 4 acute or late non-hematologic toxicities were observed. CONCLUSION: Salvage RT is an effective treatment for NSCLC patients with oligo-recurrence at regional lymph nodes. Copyright
BACKGROUND/AIM: To evaluate the outcome of definitive salvage radiotherapy (RT) in non-small cell lung cancer (NSCLC) patients with oligo-recurrence in regional lymph nodes after surgery. PATIENTS AND METHODS: Between January 2003 and December 2016, 33 patients with NSCLC were reviewed from radiotherapy database at our hospital. All patients received photon or proton salvage RT for metastases in the regional lymph nodes. RESULTS: The median follow-up from salvage RT was 35.2 (range=5.9-89.6) months. Recurrences occurred in 18 (55%) patients, and the 3-year overall and progression-free survival rates were 63.8% and 45.1%, respectively. Regional and local control improved patients' survival and these control rates were increased by use of concurrent chemotherapy (p=0.039) and proton RT (p=0.084). No grade 4 acute or late non-hematologic toxicities were observed. CONCLUSION: Salvage RT is an effective treatment for NSCLCpatients with oligo-recurrence at regional lymph nodes. Copyright
Authors: B Jeremic; Y Shibamoto; B Milicic; S Milisavljevic; N Nikolic; A Dagovic; J Aleksandrovic; G Radosavljevic-Asic Journal: Lung Cancer Date: 1999-02 Impact factor: 5.705
Authors: Zachary D Horne; Adam H Richman; Michael J Dohopolski; David A Clump; Steven A Burton; Dwight E Heron Journal: Lung Cancer Date: 2017-11-10 Impact factor: 5.705
Authors: Li Ma; Bo Qiu; Jun Zhang; Qi-Wen Li; Bin Wang; Xu-Hui Zhang; Meng-Yun Qiang; Zhao-Lin Chen; Su-Ping Guo; Hui Liu Journal: Chin J Cancer Date: 2017-12-11